MONTREAL, Nov. 28, 2020 /PRNewswire/ -- The
Montreal Heart Institute (MHI) today announced that the
COLCORONA clinical trial will continue to recruit non-hospitalized
adult patients with COVID-19 as recommended by the independent data
monitoring committee (DMC), following a second interim
analysis.
"With the dramatic rise in COVID-19 cases across the world,
it is becoming even more critical that we continue to investigate
treatments that can not only help those hospitalized with severe
disease, but also those with less severe symptoms who are able to
remain at home," said Dr. Jean-Claude
Tardif, Director of the Research Center at MHI, Professor of
Medicine at the University of Montreal,
and COLCORONA principal investigator. "We aim at completing patient
recruitment in this large study within the next month and hope that
colchicine will reduce the risk of COVID-19 complications."
COLCORONA is a contact-free, at-home, randomized,
double-blind, placebo-controlled study run out of Canada, the United
States, Europe,
South America, and South Africa. It aims to determine if
colchicine can reduce the risk of serious complications linked to
COVID-19. This is one of the few current large-scale studies of
COVID-19 in which non-hospitalized patients can participate.
Participants and physicians interested in COLCORONA can call the
hotline at 1-877-536-6837.
COLCORONA is coordinated by the Montreal Health Innovations
Coordinating Center (MHICC) and funded by the Government of
Quebec, the Bill & Melinda
Gates Foundation and the National Heart, Lung, and Blood Institute
(NHLBI) of the United States National Institutes of Health (NIH).
CGI, Dacima and Pharmascience are also collaborators of
COLCORONA.
The Montreal Heart Institute and its partners worldwide would
like to thank all the investigators and the thousands of
participants for their continued participation in the COLCORONA
study.
For more information about the study, visit
www.colcorona.net.
About the Montreal Heart Institute
Founded in 1954, the Montreal Heart Institute constantly aims
for the highest standards of excellence in the cardiovascular field
through its leadership in clinical and basic research,
ultra-specialized care, professional training, and prevention. It
houses the largest research center in Canada, the largest cardiovascular prevention
center in the country, and the largest cardiovascular genetics
center in Canada. The Institute is
affiliated with the University of
Montreal and has more than 2000 employees, including 245
doctors and more than 85 researchers.
About the Montreal Health Innovations Coordinating Center
(MHICC)
The Montreal Health Innovations Coordinating Center (MHICC) is a
leading academic clinical research organization and an integral
part of the Montreal Heart Institute (MHI). The MHICC possesses an
established network of collaborators in over 4500 clinical sites in
more than 35 countries. It has specific expertise in precision
medicine, low-cost high-quality clinical trials, and drug
repurposing.
About Pharmascience
Founded in 1983, Pharmascience Inc. is the largest
pharmaceutical employer in Quebec.
With its head office located in Montreal and its 1,500 employees,
Pharmascience Inc. is a private, full-service pharmaceutical
company with deep roots in Canada,
and whose global reach is growing, in part thanks to the
distribution of its products in more than 60 countries. Ranked 56th
among the top 100 Canadian investors in research and development
(R&D) thanks to $43 million
investment in 2018, Pharmascience Inc. is the 4th largest
manufacturer of over-the-counter generic drugs in the country.
www.pharmascience.com
About CGI
Founded in 1976, CGI is one of the world's largest information
technology (IT) and management consulting firms. From hundreds of
locations around the world, CGI offers a complete portfolio of
services and solutions: strategic IT and management consulting
services, systems integration services, intellectual property
solutions as well as IT and business process management services in
delegated mode. www.cgi.com/canada
About Dacima
Founded in 2006, Dacima Software Inc. is a leading innovator in
Electronic Data Capture (EDC) software for clinical
research. Dacima's EDC software, Dacima Clinical Suite, is a
fully feature EDC software application with integrated modules for
patient randomization (IWRS), supply management, ePRO, eDiary,
medical coding and eConsent. Dacima's flexible and highly
configurable EDC platforms allow for the design of all types of
study designs including clinical trials, patient registries,
observational studies and web surveys through an
intuitive user-friendly web
interface. www.dacimasoftware.com
Media Contacts:
Camille Turbide (Canada and Europe)
Camille.turbide@gmail.com
+ 1 514-755-5354
Christy Maginn (United States)
Christina.Maginn@havas.com
+1 (703) 297-7194